- Home
- SPRO vs ANEB Comparison
SPRO vs ANEB Comparison
Compare SPRO & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- ANEB
- Stock Information
- Founded
- SPRO 2013
- ANEB 2020
- Country
- SPRO United States
- ANEB United States
- Employees
- SPRO N/A
- ANEB N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- ANEB Biotechnology: Pharmaceutical Preparations
- Sector
- SPRO Health Care
- ANEB Health Care
- Exchange
- SPRO Nasdaq
- ANEB Nasdaq
- Market Cap
- SPRO 45.7M
- ANEB 36.7M
- IPO Year
- SPRO 2017
- ANEB 2021
- Fundamental
- Price
- SPRO $0.75
- ANEB $1.01
- Analyst Decision
- SPRO Buy
- ANEB Buy
- Analyst Count
- SPRO 4
- ANEB 1
- Target Price
- SPRO $5.00
- ANEB $8.00
- AVG Volume (30 Days)
- SPRO 218.6K
- ANEB 34.3K
- Earning Date
- SPRO 05-14-2025
- ANEB 05-14-2025
- Dividend Yield
- SPRO N/A
- ANEB N/A
- EPS Growth
- SPRO N/A
- ANEB N/A
- EPS
- SPRO N/A
- ANEB N/A
- Revenue
- SPRO $47,977,000.00
- ANEB N/A
- Revenue This Year
- SPRO N/A
- ANEB N/A
- Revenue Next Year
- SPRO N/A
- ANEB N/A
- P/E Ratio
- SPRO N/A
- ANEB N/A
- Revenue Growth
- SPRO N/A
- ANEB N/A
- 52 Week Low
- SPRO $0.51
- ANEB $0.80
- 52 Week High
- SPRO $1.72
- ANEB $3.30
- Technical
- Relative Strength Index (RSI)
- SPRO 54.69
- ANEB 39.13
- Support Level
- SPRO $0.51
- ANEB $0.94
- Resistance Level
- SPRO $0.83
- ANEB $1.12
- Average True Range (ATR)
- SPRO 0.08
- ANEB 0.13
- MACD
- SPRO 0.01
- ANEB -0.01
- Stochastic Oscillator
- SPRO 76.85
- ANEB 22.00
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.